Molecules, Vol. 23, Pages 2906: Co-Delivery of Gemcitabine and Paclitaxel in cRGD-Modified Long Circulating Nanoparticles with Asymmetric Lipid Layers for Breast Cancer Treatment
Molecules, Vol. 23, Pages 2906: Co-Delivery of Gemcitabine and Paclitaxel in cRGD-Modified Long Circulating Nanoparticles with Asymmetric Lipid Layers for Breast Cancer Treatment
Molecules doi: 10.3390/molecules23112906
Authors:
Jing Zhang
Peng Zhang
Qian Zou
Xiang Li
Jianjiang Fu
Ying Luo
Xinli Liang
Yi Jin
Combination chemotherapy is a common clinical practice in cancer treatment. Here, cyclic RGD (arginylglycylaspartic acid) peptide was introduced to the surface of lipid/calcium/phosphate (LCP) asymmetric lipid layer nanoparticles for the co-delivery of paclitaxel (PTX) and gemcitabine monophosphate (GMP) (P/G-NPs). The sphere-like morphology of P/G-NPs displays a well-distributed particle size, and high entrapment efficiency and drug loading for both PTX and GMP, with a positive zeta potential. P/G-NPs were stable for up to 15 days. The cellular uptake of these cyclic RGD-modified nanoparticles was significantly higher than that of unmodified nanoparticles over 2 h incubation. Compared with the combination of free PTX and GMP (P/G-Free), P/G-NPs exhibited a longer circulation lifetime and improved absorption for PTX and GMP. Polyethylene glycol was responsible for a higher plasma concentration and a decreased apparent volume of distribution (Vz). Nanoparticles enhanced the drug accumulation in tumors compared with other major organs after 24 h. P/G-NPs nearly halted tumor growth, with little evidence of general toxicity, whereas P/G-Free had only a m...
Source: Molecules - Category: Chemistry Authors: Jing Zhang Peng Zhang Qian Zou Xiang Li Jianjiang Fu Ying Luo Xinli Liang Yi Jin Tags: Article Source Type: research
More News: Breast Cancer | Calcium | Cancer | Cancer & Oncology | Chemistry | Chemotherapy | Lymphoma | Nanotechnology | Polyethylene Glycol | Toxicology